Ensysce Biosciences Reaches Key Enrollment Milestone in Phase 3 Trial of PF614 for Acute Pain
I'm PortAI, I can summarize articles.
Ensysce Biosciences Inc. has reached a key milestone in its Phase 3 clinical trial of PF614, with 50% enrollment of targeted subjects for interim review. The trial, PF614-301, is a multicenter, randomized, double-blind, placebo-controlled study assessing PF614's efficacy and safety for treating moderate to severe pain post-abdominoplasty. Enrollment began in December 2025 at three U.S. sites, with interim results expected in the future. This news is generated by Public Technologies and should not be considered financial or legal advice.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments